Optimization of adiponectin-derived peptides for inhibition of cancer cell growth and signaling

Laszlo Otvos, Ilona Kovalszky, Julia Olah, Roberta Coroniti, Daniel Knappe, Friederike I. Nollmann, Ralf Hoffmann, John D. Wade, Sándor Lovas, Eva Surmacz

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Adiponectin, an adipose tissue-excreted adipokine plays protective roles in metabolic and cardiovascular diseases and exerts anti-cancer activities, partially by interfering with leptin-induced signaling. Previously we identified the active site in the adiponectin protein, and generated both a nanomolar monomeric agonist of the adiponectin receptor (10-mer ADP355) and an antagonist (8-mer ADP400) to modulate various adiponectin receptor-mediated cellular functions. As physiologically circulating adiponectin forms multimeric complexes, we also generated an agonist dimer with improved biodistribution and in vitro efficacy. In the current report, we attempted to optimize the monomeric agonist structure. Neither extension of the peptide up to 14-mer analogs nor reinstallation of native residues in permissible positions enhanced significantly the activity profile. The only substitutions that resulted in 5-10-fold improved agonistic activity were the replacement of turn-forming Gly4 and Tyr7 residues with Pro and Hyp, respectively, yielding the more active native β-sheet structure. All peptides retained good stability in human serum exhibiting half-lives >2 h. The cellular efficacy and stability rankings among the peptides followed expected structure-activity relationship trends. To investigate whether simultaneous activation of adiponectin pathways and inhibition of leptin-induced signals can result in cytostatic and anti-oncogenic signal transduction processes, we developed a chimera of the leptin receptor antagonist peptide Allo-aca (placed to the N-terminus) and ADP355 (at the C-terminus). The in vitro anti-tumor activity and intracellular signaling of the chimera were dominated by the more active Allo-aca component. The ADP355 part, however, reversed unfavorable in vivo metabolic effects of the leptin receptor antagonist.

Original languageEnglish (US)
Pages (from-to)156-166
Number of pages11
JournalBiopolymers
Volume104
Issue number3
DOIs
StatePublished - May 1 2015

Fingerprint

Cell signaling
Adiponectin
Cell growth
Peptides
Adiponectin Receptors
Leptin Receptors
Growth
Leptin
Neoplasms
Signal transduction
Adipokines
Metabolic Diseases
Cytostatic Agents
Structure-Activity Relationship
Dimers
Adipose Tissue
Tumors
Signal Transduction
Catalytic Domain
Substitution reactions

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Otvos, L., Kovalszky, I., Olah, J., Coroniti, R., Knappe, D., Nollmann, F. I., ... Surmacz, E. (2015). Optimization of adiponectin-derived peptides for inhibition of cancer cell growth and signaling. Biopolymers, 104(3), 156-166. https://doi.org/10.1002/bip.22627

Optimization of adiponectin-derived peptides for inhibition of cancer cell growth and signaling. / Otvos, Laszlo; Kovalszky, Ilona; Olah, Julia; Coroniti, Roberta; Knappe, Daniel; Nollmann, Friederike I.; Hoffmann, Ralf; Wade, John D.; Lovas, Sándor; Surmacz, Eva.

In: Biopolymers, Vol. 104, No. 3, 01.05.2015, p. 156-166.

Research output: Contribution to journalArticle

Otvos, L, Kovalszky, I, Olah, J, Coroniti, R, Knappe, D, Nollmann, FI, Hoffmann, R, Wade, JD, Lovas, S & Surmacz, E 2015, 'Optimization of adiponectin-derived peptides for inhibition of cancer cell growth and signaling', Biopolymers, vol. 104, no. 3, pp. 156-166. https://doi.org/10.1002/bip.22627
Otvos L, Kovalszky I, Olah J, Coroniti R, Knappe D, Nollmann FI et al. Optimization of adiponectin-derived peptides for inhibition of cancer cell growth and signaling. Biopolymers. 2015 May 1;104(3):156-166. https://doi.org/10.1002/bip.22627
Otvos, Laszlo ; Kovalszky, Ilona ; Olah, Julia ; Coroniti, Roberta ; Knappe, Daniel ; Nollmann, Friederike I. ; Hoffmann, Ralf ; Wade, John D. ; Lovas, Sándor ; Surmacz, Eva. / Optimization of adiponectin-derived peptides for inhibition of cancer cell growth and signaling. In: Biopolymers. 2015 ; Vol. 104, No. 3. pp. 156-166.
@article{f1d6b6b386f040548290c11a43079bee,
title = "Optimization of adiponectin-derived peptides for inhibition of cancer cell growth and signaling",
abstract = "Adiponectin, an adipose tissue-excreted adipokine plays protective roles in metabolic and cardiovascular diseases and exerts anti-cancer activities, partially by interfering with leptin-induced signaling. Previously we identified the active site in the adiponectin protein, and generated both a nanomolar monomeric agonist of the adiponectin receptor (10-mer ADP355) and an antagonist (8-mer ADP400) to modulate various adiponectin receptor-mediated cellular functions. As physiologically circulating adiponectin forms multimeric complexes, we also generated an agonist dimer with improved biodistribution and in vitro efficacy. In the current report, we attempted to optimize the monomeric agonist structure. Neither extension of the peptide up to 14-mer analogs nor reinstallation of native residues in permissible positions enhanced significantly the activity profile. The only substitutions that resulted in 5-10-fold improved agonistic activity were the replacement of turn-forming Gly4 and Tyr7 residues with Pro and Hyp, respectively, yielding the more active native β-sheet structure. All peptides retained good stability in human serum exhibiting half-lives >2 h. The cellular efficacy and stability rankings among the peptides followed expected structure-activity relationship trends. To investigate whether simultaneous activation of adiponectin pathways and inhibition of leptin-induced signals can result in cytostatic and anti-oncogenic signal transduction processes, we developed a chimera of the leptin receptor antagonist peptide Allo-aca (placed to the N-terminus) and ADP355 (at the C-terminus). The in vitro anti-tumor activity and intracellular signaling of the chimera were dominated by the more active Allo-aca component. The ADP355 part, however, reversed unfavorable in vivo metabolic effects of the leptin receptor antagonist.",
author = "Laszlo Otvos and Ilona Kovalszky and Julia Olah and Roberta Coroniti and Daniel Knappe and Nollmann, {Friederike I.} and Ralf Hoffmann and Wade, {John D.} and S{\'a}ndor Lovas and Eva Surmacz",
year = "2015",
month = "5",
day = "1",
doi = "10.1002/bip.22627",
language = "English (US)",
volume = "104",
pages = "156--166",
journal = "Biopolymers",
issn = "0006-3525",
publisher = "John Wiley and Sons Inc.",
number = "3",

}

TY - JOUR

T1 - Optimization of adiponectin-derived peptides for inhibition of cancer cell growth and signaling

AU - Otvos, Laszlo

AU - Kovalszky, Ilona

AU - Olah, Julia

AU - Coroniti, Roberta

AU - Knappe, Daniel

AU - Nollmann, Friederike I.

AU - Hoffmann, Ralf

AU - Wade, John D.

AU - Lovas, Sándor

AU - Surmacz, Eva

PY - 2015/5/1

Y1 - 2015/5/1

N2 - Adiponectin, an adipose tissue-excreted adipokine plays protective roles in metabolic and cardiovascular diseases and exerts anti-cancer activities, partially by interfering with leptin-induced signaling. Previously we identified the active site in the adiponectin protein, and generated both a nanomolar monomeric agonist of the adiponectin receptor (10-mer ADP355) and an antagonist (8-mer ADP400) to modulate various adiponectin receptor-mediated cellular functions. As physiologically circulating adiponectin forms multimeric complexes, we also generated an agonist dimer with improved biodistribution and in vitro efficacy. In the current report, we attempted to optimize the monomeric agonist structure. Neither extension of the peptide up to 14-mer analogs nor reinstallation of native residues in permissible positions enhanced significantly the activity profile. The only substitutions that resulted in 5-10-fold improved agonistic activity were the replacement of turn-forming Gly4 and Tyr7 residues with Pro and Hyp, respectively, yielding the more active native β-sheet structure. All peptides retained good stability in human serum exhibiting half-lives >2 h. The cellular efficacy and stability rankings among the peptides followed expected structure-activity relationship trends. To investigate whether simultaneous activation of adiponectin pathways and inhibition of leptin-induced signals can result in cytostatic and anti-oncogenic signal transduction processes, we developed a chimera of the leptin receptor antagonist peptide Allo-aca (placed to the N-terminus) and ADP355 (at the C-terminus). The in vitro anti-tumor activity and intracellular signaling of the chimera were dominated by the more active Allo-aca component. The ADP355 part, however, reversed unfavorable in vivo metabolic effects of the leptin receptor antagonist.

AB - Adiponectin, an adipose tissue-excreted adipokine plays protective roles in metabolic and cardiovascular diseases and exerts anti-cancer activities, partially by interfering with leptin-induced signaling. Previously we identified the active site in the adiponectin protein, and generated both a nanomolar monomeric agonist of the adiponectin receptor (10-mer ADP355) and an antagonist (8-mer ADP400) to modulate various adiponectin receptor-mediated cellular functions. As physiologically circulating adiponectin forms multimeric complexes, we also generated an agonist dimer with improved biodistribution and in vitro efficacy. In the current report, we attempted to optimize the monomeric agonist structure. Neither extension of the peptide up to 14-mer analogs nor reinstallation of native residues in permissible positions enhanced significantly the activity profile. The only substitutions that resulted in 5-10-fold improved agonistic activity were the replacement of turn-forming Gly4 and Tyr7 residues with Pro and Hyp, respectively, yielding the more active native β-sheet structure. All peptides retained good stability in human serum exhibiting half-lives >2 h. The cellular efficacy and stability rankings among the peptides followed expected structure-activity relationship trends. To investigate whether simultaneous activation of adiponectin pathways and inhibition of leptin-induced signals can result in cytostatic and anti-oncogenic signal transduction processes, we developed a chimera of the leptin receptor antagonist peptide Allo-aca (placed to the N-terminus) and ADP355 (at the C-terminus). The in vitro anti-tumor activity and intracellular signaling of the chimera were dominated by the more active Allo-aca component. The ADP355 part, however, reversed unfavorable in vivo metabolic effects of the leptin receptor antagonist.

UR - http://www.scopus.com/inward/record.url?scp=84979993247&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84979993247&partnerID=8YFLogxK

U2 - 10.1002/bip.22627

DO - 10.1002/bip.22627

M3 - Article

VL - 104

SP - 156

EP - 166

JO - Biopolymers

JF - Biopolymers

SN - 0006-3525

IS - 3

ER -